Arcellx, Inc. (ACLX) 10-Year Financial Performance & Capital Metrics

ACLX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutArcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.Show more

Revenue $108M -2.2%
EBITDA -$132M -50.7%
Net Income -$107M -51.9%
EPS (Diluted) -2.00 -36.1%
Gross Margin 95.19% -4.8%
EBITDA Margin -122.65% -54.0%
Operating Margin -127.46% -56.4%
Net Margin -99.46% -55.2%
ROE -22.84% -11.5%
ROIC -34.88% -8.0%
Debt/Equity 0.12 -40.9%
Interest Coverage -133.56 -470.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 11.5% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-76.96%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-439.06%

EPS CAGR

10Y-

5Y-

3Y-

TTM-425.33%

ROCE

10Y Avg-59.36%

5Y Avg-58.05%

3Y Avg-47.67%

Latest-21.28%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	110.32M	107.94M
Revenue Growth %	-	-	-	-	-	-	-0.02%
Cost of Goods Sold+	0	326K	0	0	2.22M	0	5.19M
COGS % of Revenue	-	-	-	-	-	-	0.05%
Gross Profit+	0	-326K	0	0	-2.22M	110.32M	102.75M
Gross Margin %	-	-	-	-	-	1%	0.95%
Gross Profit Growth %	-	-	1%	-	-	50.6%	-0.07%
Operating Expenses+	8.31M	17.97M	32.1M	65.02M	189.03M	200.2M	240.32M
OpEx % of Revenue	-	-	-	-	-	1.81%	2.23%
Selling, General & Admin	2.2M	2.21M	7.04M	18.14M	41.7M	66.35M	88.41M
SG&A % of Revenue	-	-	-	-	-	0.6%	0.82%
Research & Development	6.11M	15.77M	25.06M	46.88M	149.56M	133.85M	157.09M
R&D % of Revenue	-	-	-	-	-	1.21%	1.46%
Other Operating Expenses	0	0	-1	0	-2.22M	0	-5.19M
Operating Income+	-8.31M	-17.97M	-32.1M	-65.02M	-191.26M	-89.88M	-137.57M
Operating Margin %	-	-	-	-	-	-0.81%	-1.27%
Operating Income Growth %	-	-1.16%	-0.79%	-1.03%	-1.94%	0.53%	-0.53%
EBITDA+	-8.22M	-17.65M	-31.47M	-63.98M	-189.03M	-87.84M	-132.38M
EBITDA Margin %	-	-	-	-	-	-0.8%	-1.23%
EBITDA Growth %	-	-1.15%	-0.78%	-1.03%	-1.95%	0.54%	-0.51%
D&A (Non-Cash Add-back)	93K	326K	629K	1.04M	2.22M	2.04M	5.19M
EBIT	-8.31M	-17.97M	-32.1M	-64.96M	-186.96M	-66.19M	-104.25M
Net Interest Income+	0	0	1K	290K	2.58M	19.85M	32.29M
Interest Income	0	0	1K	300K	4.3M	23.7M	33.32M
Interest Expense	0	0	0	10K	1.72M	3.84M	1.03M
Other Income/Expense	999	2K	999	49K	2.58M	19.85M	32.29M
Pretax Income+	-8.31M	-17.97M	-32.09M	-64.97M	-188.68M	-70.03M	-105.28M
Pretax Margin %	-	-	-	-	-	-0.63%	-0.98%
Income Tax+	0	0	0	0	0	663K	2.07M
Effective Tax Rate %	1%	1%	1%	1%	1%	1.01%	1.02%
Net Income+	-8.31M	-17.97M	-32.09M	-64.97M	-188.68M	-70.69M	-107.35M
Net Margin %	-	-	-	-	-	-0.64%	-0.99%
Net Income Growth %	-	-1.16%	-0.79%	-1.02%	-1.9%	0.63%	-0.52%
Net Income (Continuing)	-8.31M	-17.97M	-32.09M	-64.97M	-188.68M	-70.69M	-107.35M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-50.17	-0.52	-1.47	-1.94	-4.28	-1.47	-2.00
EPS Growth %	-	0.99%	-1.83%	-0.32%	-1.21%	0.66%	-0.36%
EPS (Basic)	-50.17	-0.52	-1.47	-1.94	-4.28	-1.47	-2.00
Diluted Shares Outstanding	165.58K	34.78M	21.78M	33.54M	44.11M	48.06M	53.57M
Basic Shares Outstanding	165.58K	34.78M	21.78M	33.54M	44.11M	48.06M	53.57M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	14.63M	38.07M	49.36M	112.81M	266.86M	716.36M	599.31M
Cash & Short-Term Investments	14.53M	34.58M	46.6M	104.62M	254.84M	702.02M	587.38M
Cash Only	14.53M	34.58M	46.6M	30.83M	64.18M	394.58M	105.68M
Short-Term Investments	0	0	0	73.78M	190.66M	307.43M	481.7M
Accounts Receivable	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	99K	621K	1.21M	2.05M	3.67M	7.58M	6.05M
Total Non-Current Assets+	1.18M	5.52M	8.34M	15.97M	46.95M	108.77M	112.02M
Property, Plant & Equipment	817K	4.33M	4.9M	10.32M	39.89M	69.83M	70.25M
Fixed Asset Turnover	-	-	-	-	-	1.58x	1.54x
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	0	0	199K	0	0	27.17M	38.28M
Other Non-Current Assets	366K	1.19M	3.24M	5.66M	7.06M	11.77M	3.5M
Total Assets+	15.81M	43.59M	57.69M	128.78M	313.82M	825.13M	711.33M
Asset Turnover	-	-	-	-	-	0.13x	0.15x
Asset Growth %	-	1.76%	0.32%	1.23%	1.44%	1.63%	-0.14%
Total Current Liabilities+	1.82M	3.04M	5.27M	14.85M	56.69M	118.24M	125.41M
Accounts Payable	1.05M	1.75M	504K	1.33M	9.05M	2.62M	2.1M
Days Payables Outstanding	-	1.95K	-	-	1.49K	-	147.39
Short-Term Debt	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	1000K	1000K
Other Current Liabilities	766K	1.05M	3.4M	5.58M	8.48M	13.74M	18.97M
Current Ratio	8.06x	12.53x	9.36x	7.60x	4.71x	6.06x	4.78x
Quick Ratio	8.06x	12.53x	9.36x	7.60x	4.71x	6.06x	4.78x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	73.29M	1.88M	235.45M	52.17M	221.51M	131.13M
Long-Term Debt	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	52.17M	50.84M	46.54M
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	73.29M	1.88M	235.45M	0	0	8.59M
Total Liabilities	1.82M	76.33M	7.15M	250.3M	108.86M	339.75M	256.54M
Total Debt+	0	0	0	0	88.13M	97.63M	54.08M
Net Debt	-14.53M	-34.58M	-46.6M	-30.83M	23.95M	-296.96M	-51.6M
Debt / Equity	-	-	-	-	0.43x	0.20x	0.12x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-6501.80x	-111.20x	-23.39x	-133.56x
Total Equity+	13.96M	-32.74M	50.54M	-121.52M	204.95M	485.38M	454.79M
Equity Growth %	-	-3.35%	2.54%	-3.4%	2.69%	1.37%	-0.06%
Book Value per Share	84.30	-0.94	2.32	-3.62	4.65	10.10	8.49
Total Shareholders' Equity	13.96M	-32.74M	50.54M	-121.52M	204.95M	485.38M	454.79M
Common Stock	1K	1K	2K	1K	44K	52K	53K
Retained Earnings	-15.07M	-33.05M	-65.14M	-130.11M	-318.79M	-389.48M	-496.83M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	-20K	-221K	547K	848K
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-6.86M	-18.77M	-28.66M	-54.24M	-99.3M	207.57M	-83.47M
Operating CF Margin %	-	-	-	-	-	1.88%	-0.77%
Operating CF Growth %	-	-1.74%	-0.53%	-0.89%	-0.83%	3.09%	-1.4%
Net Income	-8.31M	-17.97M	-32.09M	-64.97M	-188.68M	-70.69M	-107.35M
Depreciation & Amortization	93K	326K	629K	1.04M	1.32M	2.04M	5.19M
Stock-Based Compensation	66K	136K	1.05M	6.75M	21.54M	41.79M	61.09M
Deferred Taxes	0	0	0	0	0	0	0
Other Non-Cash Items	856K	0	0	213K	62.06M	9.01M	-11.62M
Working Capital Changes	432K	-1.26M	1.75M	2.72M	4.45M	225.43M	-30.78M
Change in Receivables	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	0	688K	-1.33M	974K	7.42M	-6.47M	-70K
Cash from Investing+	-479K	-3.83M	-888K	-79.98M	-117.67M	-154.51M	-183.04M
Capital Expenditures	-479K	-3.83M	-888K	-5.78M	-2.28M	-21.43M	-13.43M
CapEx % of Revenue	-	-	-	-	-	0.19%	0.12%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	0	-115.4M	0	0
Cash from Financing+	12.48M	42.65M	41.66M	118.45M	252.63M	279.16M	-24.09M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	12.48M	86K	-1.15M	-256K	2.47M	8.85M	0
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-7.34M	-22.6M	-29.55M	-60.02M	-101.58M	186.15M	-96.9M
FCF Margin %	-	-	-	-	-	1.69%	-0.9%
FCF Growth %	-	-2.08%	-0.31%	-1.03%	-0.69%	2.83%	-1.52%
FCF per Share	-44.33	-0.65	-1.36	-1.79	-2.30	3.87	-1.81
FCF Conversion (FCF/Net Income)	0.83x	1.04x	0.89x	0.83x	0.53x	-2.94x	0.78x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	212K	1.64M

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-59.52%	-	-360.56%	-	-452.26%	-20.48%	-22.84%
Return on Invested Capital (ROIC)	-	-	-	-	-374.73%	-32.31%	-34.88%
Gross Margin	-	-	-	-	-	100%	95.19%
Net Margin	-	-	-	-	-	-64.08%	-99.46%
Debt / Equity	-	-	-	-	0.43x	0.20x	0.12x
Interest Coverage	-	-	-	-6501.80x	-111.20x	-23.39x	-133.56x
FCF Conversion	0.83x	1.04x	0.89x	0.83x	0.53x	-2.94x	0.78x
Revenue Growth	-	-	-	-	-	-	-2.16%

Frequently Asked Questions

Growth & Financials

Arcellx, Inc. (ACLX) reported $35.9M in revenue for fiscal year 2024.

Arcellx, Inc. (ACLX) saw revenue decline by 2.2% over the past year.

Arcellx, Inc. (ACLX) reported a net loss of $217.9M for fiscal year 2024.

Dividend & Returns

Arcellx, Inc. (ACLX) has a return on equity (ROE) of -22.8%. Negative ROE indicates the company is unprofitable.

Arcellx, Inc. (ACLX) had negative free cash flow of $201.2M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

Arcellx, Inc. (ACLX) 10-Year Financial Performance & Capital Metrics

ACLX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $108M -2.2%
EBITDA -$132M -50.7%
Net Income -$107M -51.9%
EPS (Diluted) -2.00 -36.1%
Gross Margin 95.19% -4.8%
EBITDA Margin -122.65% -54.0%
Operating Margin -127.46% -56.4%
Net Margin -99.46% -55.2%
ROE -22.84% -11.5%
ROIC -34.88% -8.0%
Debt/Equity 0.12 -40.9%
Interest Coverage -133.56 -470.9%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 11.5% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-76.96%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-439.06%

EPS CAGR

10Y-

5Y-

3Y-

TTM-425.33%

ROCE

10Y Avg-59.36%

5Y Avg-58.05%

3Y Avg-47.67%

Latest-21.28%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	110.32M	107.94M
Revenue Growth %	-	-	-	-	-	-	-0.02%
Cost of Goods Sold+	0	326K	0	0	2.22M	0	5.19M
COGS % of Revenue	-	-	-	-	-	-	0.05%
Gross Profit+	0	-326K	0	0	-2.22M	110.32M	102.75M
Gross Margin %	-	-	-	-	-	1%	0.95%
Gross Profit Growth %	-	-	1%	-	-	50.6%	-0.07%
Operating Expenses+	8.31M	17.97M	32.1M	65.02M	189.03M	200.2M	240.32M
OpEx % of Revenue	-	-	-	-	-	1.81%	2.23%
Selling, General & Admin	2.2M	2.21M	7.04M	18.14M	41.7M	66.35M	88.41M
SG&A % of Revenue	-	-	-	-	-	0.6%	0.82%
Research & Development	6.11M	15.77M	25.06M	46.88M	149.56M	133.85M	157.09M
R&D % of Revenue	-	-	-	-	-	1.21%	1.46%
Other Operating Expenses	0	0	-1	0	-2.22M	0	-5.19M
Operating Income+	-8.31M	-17.97M	-32.1M	-65.02M	-191.26M	-89.88M	-137.57M
Operating Margin %	-	-	-	-	-	-0.81%	-1.27%
Operating Income Growth %	-	-1.16%	-0.79%	-1.03%	-1.94%	0.53%	-0.53%
EBITDA+	-8.22M	-17.65M	-31.47M	-63.98M	-189.03M	-87.84M	-132.38M
EBITDA Margin %	-	-	-	-	-	-0.8%	-1.23%
EBITDA Growth %	-	-1.15%	-0.78%	-1.03%	-1.95%	0.54%	-0.51%
D&A (Non-Cash Add-back)	93K	326K	629K	1.04M	2.22M	2.04M	5.19M
EBIT	-8.31M	-17.97M	-32.1M	-64.96M	-186.96M	-66.19M	-104.25M
Net Interest Income+	0	0	1K	290K	2.58M	19.85M	32.29M
Interest Income	0	0	1K	300K	4.3M	23.7M	33.32M
Interest Expense	0	0	0	10K	1.72M	3.84M	1.03M
Other Income/Expense	999	2K	999	49K	2.58M	19.85M	32.29M
Pretax Income+	-8.31M	-17.97M	-32.09M	-64.97M	-188.68M	-70.03M	-105.28M
Pretax Margin %	-	-	-	-	-	-0.63%	-0.98%
Income Tax+	0	0	0	0	0	663K	2.07M
Effective Tax Rate %	1%	1%	1%	1%	1%	1.01%	1.02%
Net Income+	-8.31M	-17.97M	-32.09M	-64.97M	-188.68M	-70.69M	-107.35M
Net Margin %	-	-	-	-	-	-0.64%	-0.99%
Net Income Growth %	-	-1.16%	-0.79%	-1.02%	-1.9%	0.63%	-0.52%
Net Income (Continuing)	-8.31M	-17.97M	-32.09M	-64.97M	-188.68M	-70.69M	-107.35M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-50.17	-0.52	-1.47	-1.94	-4.28	-1.47	-2.00
EPS Growth %	-	0.99%	-1.83%	-0.32%	-1.21%	0.66%	-0.36%
EPS (Basic)	-50.17	-0.52	-1.47	-1.94	-4.28	-1.47	-2.00
Diluted Shares Outstanding	165.58K	34.78M	21.78M	33.54M	44.11M	48.06M	53.57M
Basic Shares Outstanding	165.58K	34.78M	21.78M	33.54M	44.11M	48.06M	53.57M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	14.63M	38.07M	49.36M	112.81M	266.86M	716.36M	599.31M
Cash & Short-Term Investments	14.53M	34.58M	46.6M	104.62M	254.84M	702.02M	587.38M
Cash Only	14.53M	34.58M	46.6M	30.83M	64.18M	394.58M	105.68M
Short-Term Investments	0	0	0	73.78M	190.66M	307.43M	481.7M
Accounts Receivable	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	99K	621K	1.21M	2.05M	3.67M	7.58M	6.05M
Total Non-Current Assets+	1.18M	5.52M	8.34M	15.97M	46.95M	108.77M	112.02M
Property, Plant & Equipment	817K	4.33M	4.9M	10.32M	39.89M	69.83M	70.25M
Fixed Asset Turnover	-	-	-	-	-	1.58x	1.54x
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	0	0	199K	0	0	27.17M	38.28M
Other Non-Current Assets	366K	1.19M	3.24M	5.66M	7.06M	11.77M	3.5M
Total Assets+	15.81M	43.59M	57.69M	128.78M	313.82M	825.13M	711.33M
Asset Turnover	-	-	-	-	-	0.13x	0.15x
Asset Growth %	-	1.76%	0.32%	1.23%	1.44%	1.63%	-0.14%
Total Current Liabilities+	1.82M	3.04M	5.27M	14.85M	56.69M	118.24M	125.41M
Accounts Payable	1.05M	1.75M	504K	1.33M	9.05M	2.62M	2.1M
Days Payables Outstanding	-	1.95K	-	-	1.49K	-	147.39
Short-Term Debt	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	1000K	1000K
Other Current Liabilities	766K	1.05M	3.4M	5.58M	8.48M	13.74M	18.97M
Current Ratio	8.06x	12.53x	9.36x	7.60x	4.71x	6.06x	4.78x
Quick Ratio	8.06x	12.53x	9.36x	7.60x	4.71x	6.06x	4.78x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	73.29M	1.88M	235.45M	52.17M	221.51M	131.13M
Long-Term Debt	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	52.17M	50.84M	46.54M
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	73.29M	1.88M	235.45M	0	0	8.59M
Total Liabilities	1.82M	76.33M	7.15M	250.3M	108.86M	339.75M	256.54M
Total Debt+	0	0	0	0	88.13M	97.63M	54.08M
Net Debt	-14.53M	-34.58M	-46.6M	-30.83M	23.95M	-296.96M	-51.6M
Debt / Equity	-	-	-	-	0.43x	0.20x	0.12x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-6501.80x	-111.20x	-23.39x	-133.56x
Total Equity+	13.96M	-32.74M	50.54M	-121.52M	204.95M	485.38M	454.79M
Equity Growth %	-	-3.35%	2.54%	-3.4%	2.69%	1.37%	-0.06%
Book Value per Share	84.30	-0.94	2.32	-3.62	4.65	10.10	8.49
Total Shareholders' Equity	13.96M	-32.74M	50.54M	-121.52M	204.95M	485.38M	454.79M
Common Stock	1K	1K	2K	1K	44K	52K	53K
Retained Earnings	-15.07M	-33.05M	-65.14M	-130.11M	-318.79M	-389.48M	-496.83M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	-20K	-221K	547K	848K
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-6.86M	-18.77M	-28.66M	-54.24M	-99.3M	207.57M	-83.47M
Operating CF Margin %	-	-	-	-	-	1.88%	-0.77%
Operating CF Growth %	-	-1.74%	-0.53%	-0.89%	-0.83%	3.09%	-1.4%
Net Income	-8.31M	-17.97M	-32.09M	-64.97M	-188.68M	-70.69M	-107.35M
Depreciation & Amortization	93K	326K	629K	1.04M	1.32M	2.04M	5.19M
Stock-Based Compensation	66K	136K	1.05M	6.75M	21.54M	41.79M	61.09M
Deferred Taxes	0	0	0	0	0	0	0
Other Non-Cash Items	856K	0	0	213K	62.06M	9.01M	-11.62M
Working Capital Changes	432K	-1.26M	1.75M	2.72M	4.45M	225.43M	-30.78M
Change in Receivables	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	0	688K	-1.33M	974K	7.42M	-6.47M	-70K
Cash from Investing+	-479K	-3.83M	-888K	-79.98M	-117.67M	-154.51M	-183.04M
Capital Expenditures	-479K	-3.83M	-888K	-5.78M	-2.28M	-21.43M	-13.43M
CapEx % of Revenue	-	-	-	-	-	0.19%	0.12%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	0	-115.4M	0	0
Cash from Financing+	12.48M	42.65M	41.66M	118.45M	252.63M	279.16M	-24.09M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	12.48M	86K	-1.15M	-256K	2.47M	8.85M	0
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-7.34M	-22.6M	-29.55M	-60.02M	-101.58M	186.15M	-96.9M
FCF Margin %	-	-	-	-	-	1.69%	-0.9%
FCF Growth %	-	-2.08%	-0.31%	-1.03%	-0.69%	2.83%	-1.52%
FCF per Share	-44.33	-0.65	-1.36	-1.79	-2.30	3.87	-1.81
FCF Conversion (FCF/Net Income)	0.83x	1.04x	0.89x	0.83x	0.53x	-2.94x	0.78x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	212K	1.64M

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-59.52%	-	-360.56%	-	-452.26%	-20.48%	-22.84%
Return on Invested Capital (ROIC)	-	-	-	-	-374.73%	-32.31%	-34.88%
Gross Margin	-	-	-	-	-	100%	95.19%
Net Margin	-	-	-	-	-	-64.08%	-99.46%
Debt / Equity	-	-	-	-	0.43x	0.20x	0.12x
Interest Coverage	-	-	-	-6501.80x	-111.20x	-23.39x	-133.56x
FCF Conversion	0.83x	1.04x	0.89x	0.83x	0.53x	-2.94x	0.78x
Revenue Growth	-	-	-	-	-	-	-2.16%

Frequently Asked Questions

Growth & Financials

Arcellx, Inc. (ACLX) reported $35.9M in revenue for fiscal year 2024.

Arcellx, Inc. (ACLX) saw revenue decline by 2.2% over the past year.

Arcellx, Inc. (ACLX) reported a net loss of $217.9M for fiscal year 2024.

Dividend & Returns

Arcellx, Inc. (ACLX) has a return on equity (ROE) of -22.8%. Negative ROE indicates the company is unprofitable.

Arcellx, Inc. (ACLX) had negative free cash flow of $201.2M in fiscal year 2024, likely due to heavy capital investments.